Hypercholesterolaemia: optimal treatment by next-generation drugs?
作者信息
van der Wall E E
机构信息
Netherlands Society of Cardiology/Holland Heart House, Moreelsepark 1, 3511 EP, Utrecht, The Netherlands.
出版信息
Neth Heart J. 2015 Sep;23(10):455-456. doi: 10.1007/s12471-015-0741-2.
Abstract
摘要
相似文献
1
Hypercholesterolaemia: optimal treatment by next-generation drugs?高胆固醇血症：新一代药物的最佳治疗方法？
Neth Heart J. 2015 Sep;23(10):455-456. doi: 10.1007/s12471-015-0741-2.
2
Molecular testing for familial hypercholesterolaemia-associated mutations in a UK-based cohort: development of an NGS-based method and comparison with multiplex polymerase chain reaction and oligonucleotide arrays.
Ann Clin Biochem. 2016 Nov;53(6):654-662. doi: 10.1177/0004563216629170. Epub 2016 Sep 28.
3
Molecular diagnosis of familial hypercholesterolaemia.家族性高胆固醇血症的分子诊断
Curr Opin Lipidol. 2017 Aug;28(4):313-320. doi: 10.1097/MOL.0000000000000430.
4
Hypercholesterolaemia and its treatment in Singapore with implications for screening.
Ann Acad Med Singap. 1997 Jul;26(4):449-52.
5
Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?拓宽家族性高胆固醇血症的基因检测范围：这将转化为更好的患者和人群结局吗？
Clin Genet. 2020 Apr;97(4):543-555. doi: 10.1111/cge.13685. Epub 2019 Dec 27.
6
Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing.家族性高胆固醇血症的靶向下一代测序基因诊断。
J Intern Med. 2014 Oct;276(4):396-403. doi: 10.1111/joim.12263. Epub 2014 May 21.
7
Dietary treatment for familial hypercholesterolaemia.家族性高胆固醇血症的饮食治疗
Cochrane Database Syst Rev. 2001(2):CD001918. doi: 10.1002/14651858.CD001918.
8
Importance of early recognition of heterozygous familial hypercholesterolaemia.早期识别杂合子家族性高胆固醇血症的重要性。
Curr Opin Lipidol. 2015 Aug;26(4):298-303. doi: 10.1097/MOL.0000000000000196.
9
Homozygous familial hypercholesterolaemia: update on management.纯合子家族性高胆固醇血症：管理进展
Paediatr Int Child Health. 2016 Nov;36(4):243-247. doi: 10.1080/20469047.2016.1246640.
10
Familial hypercholesterolaemia.家族性高胆固醇血症
Curr Opin Cardiol. 2014 Jul;29(4):381-8. doi: 10.1097/HCO.0000000000000083.
本文引用的文献
1
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.儿童和青少年家族性高胆固醇血症：通过优化检测与治疗延长数十年寿命
Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25.
2
PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素9抑制剂：治疗高胆固醇血症的新型治疗药物。
Eur J Pharmacol. 2015 Sep 15;763(Pt A):38-47. doi: 10.1016/j.ejphar.2015.03.099. Epub 2015 May 16.
3
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制剂：过去、现在和未来。
Eur Heart J. 2015 Sep 21;36(36):2415-24. doi: 10.1093/eurheartj/ehv174. Epub 2015 May 12.
4
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.依洛尤单抗降低血脂和心血管事件的疗效和安全性。
N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.
5
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.阿利西尤单抗在接受最大耐受剂量他汀类药物治疗但高胆固醇血症控制不佳的高心血管风险患者中的疗效和安全性：ODYSSEY COMBO II随机对照试验
Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16.
6
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.依洛尤单抗，一种针对前蛋白转化酶枯草溶菌素 9（PCSK9）的单克隆抗体，对急性冠脉综合征后长期心血管结局的影响：ODYSSEY 结局试验的原理和设计。
Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.
7
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.阿利西尤单抗可抑制动脉粥样硬化，改善斑块形态，并增强他汀类药物的疗效。
J Lipid Res. 2014 Oct;55(10):2103-12. doi: 10.1194/jlr.M051326. Epub 2014 Aug 19.
8
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.在高胆固醇血症患者中，前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂阿利西尤单抗与依折麦布单药治疗的比较：一项24周、双盲、随机3期试验的结果
Int J Cardiol. 2014 Sep;176(1):55-61. doi: 10.1016/j.ijcard.2014.06.049. Epub 2014 Jul 2.
9
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.依洛尤单抗治疗高胆固醇血症的抗-前蛋白转化酶枯草溶菌素 9 单药治疗：MENDEL-2 随机、对照、III 期临床研究。
J Am Coll Cardiol. 2014 Jun 17;63(23):2531-2540. doi: 10.1016/j.jacc.2014.03.018. Epub 2014 Mar 29.
10
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.荷兰常染色体显性遗传高胆固醇血症的纯合子：患病率、基因型-表型关系和临床结局。
Eur Heart J. 2015 Mar 1;36(9):560-5. doi: 10.1093/eurheartj/ehu058. Epub 2014 Feb 28.
Zotero 插件